To further confirm that the phenotype observed in ACC cells treated with PRT543 indeed resulted from a direct inhibition of PRMT5 activity, we treated the cell lines and organoid models with PRT811, another potent, highly selective (Supplementary Fig. 6), and orally bioavailable brain penetrant PRMT5 inhibitor [104]. The gene discussed is PRMT5; the disease is adrenal cortex carcinoma.